Stocks · News reference
Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 11:06 AM
- Checked
- Aug 12, 2026, 11:06 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cantor Fitzgerald Reiterates Overweight on Cypherpunk Technologies, Maintains $1.6 Price Target
Cantor Fitzgerald analyst Nathan Frankovitz reiterates Cypherpunk Technologies (NASDAQ:CYPH) with a Overweight and maintains $1.6 price target.
Read original at benzingaWhy Planet Green Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Planet Green Holdings Corp (NYSE: PLAG) saw a sharp increase in pre-market trading after Curvature Securities terminated their sales agreement.
Read original at benzinga12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings came out 3
Read original at benzinga